Předmět: |
|
Zdroj: |
Hematology Week; 8/31/2023, p990-990, 1p |
Abstrakt: |
Keywords: San Francisco; State:California; United States; North and Central America; Cancer; Enzymes and Coenzymes; Genetics; Health and Medicine; Hematology; Immunoproliferative Disorders; Kinase; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Melanoma; Oncology EN San Francisco State:California United States North and Central America Cancer Enzymes and Coenzymes Genetics Health and Medicine Hematology Immunoproliferative Disorders Kinase Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Melanoma Oncology 990 990 1 08/28/23 20230831 NES 230831 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in Oncology - Lymphoma. According to the news editors, the research concluded: "As ALK kinase inhibitors are effective against a range of tumors with similar ALK fusion kinases, identifying ALK fusion genes in congenital melanocytic nevi may provide an opportunity for targeted therapy.". [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|